Trials / Completed
CompletedNCT00159887
Study to Assess the Longterm Safety of Sildenafil Citrate in Patients With Pulmonary Arterial Hypertension
A Multi-Centre, Multinational, Long-Term Extension Study, to Assess the Safety and Toleration of Subject Optimised Treatment Regimens of Oral Sildenafil Citrate for Pulmonary Arterial Hypertension in Subjects Who Have Completed Study A1481140.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 260 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Open label extension study to the pivotal efficacy study to assess the safety of sildenafil citrate in patients with pulmonary arterial hypertension
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sildenafil citrate |
Timeline
- Start date
- 2002-12-01
- Completion
- 2007-02-01
- First posted
- 2005-09-12
- Last updated
- 2021-02-01
Locations
65 sites across 22 countries: United States, Australia, Belgium, Brazil, Czechia, Denmark, France, Germany, Hong Kong, Hungary, Israel, Italy, Malaysia, Mexico, Netherlands, Poland, Singapore, South Africa, South Korea, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00159887. Inclusion in this directory is not an endorsement.